The PBMC transcriptome profile after intake of oxidized versus high-quality fish oil: an explorative study in healthy subjects

Mari C. W. Myhrstad1*, Inger Ottestad2,1, Clara-Cecilie Günther3, Einar Ryeng4, Marit Holden3, Astrid Nilsson5, Kirsti W. Brønner6, Achim Kohler5,7, Grethe I. A. Borge5, Kirsten B. Holven2,8 and Stine M. Ulven1,2

Abstract

Background: Marine long-chain polyunsaturated fatty acids are susceptible to oxidation, generating a range of different oxidation products with suggested negative health effects. The aim of the present study was to utilize sensitive high-throughput transcriptome analyses to investigate potential unfavorable effects of oxidized fish oil (PV: 18 meq/kg; AV: 9) compared to high-quality fish oil (PV: 4 meq/kg; AV: 3).

Methods: In a double-blinded randomized controlled study for seven weeks, 35 healthy subjects were assigned to 8 g of either oxidized fish oil or high quality fish oil. The daily dose of EPA+DHA was 1.6 g. Peripheral blood mononuclear cells were isolated at baseline and after 7 weeks and transcriptome analyses were performed with the illuminaHT-12 v4 Expression BeadChip.

Results: No gene transcripts, biological processes, pathway or network were significantly changed in the oxidized fish oil group compared to the fish oil group. Furthermore, gene sets related to oxidative stress and cardiovascular disease were not differently regulated between the groups. Within group analyses revealed a more prominent effect after intake of high quality fish oil as 11 gene transcripts were significantly (FDR < 0.1) changed from baseline versus three within the oxidized fish oil group.

Conclusion: The suggested concern linking lipid oxidation products to short-term unfavorable health effects may therefore not be evident at a molecular level in this explorative study.

Trial registration: ClinicalTrials.gov, NCT01034423

Keywords: Oxidized fish oil, n-3 fatty acids, PBMCs, Transcriptome, Human intervention

Background

Fish oil (FO) is associated with reduced risk of coronary heart disease (CHD) and CHD deaths [1, 2]; thus, the use of supplements containing n-3 fatty acids are recommended for CHD prevention among those who do not eat fish in accordance with the food recommendations [3–5]. Long-chain polyunsaturated fatty acids (LCPU-FAs), including n-3 fatty acids in marine oils, are susceptible to oxidation, and consequently, lipid oxidation products are generated [6–8]. For several years, the voluntary monographs by the Global Organization for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) Omega-3s (GOED) have served as the quality standard of the industry, giving recommendations for the content of lipid oxidation products, such as a maximum peroxide value (PV) of 5 meq/kg (milliequivalents per kilogram) and a maximum anisidine value (AV) of 20 [9]. Other monographs exists, such as the European pharmacopeia recommending a PV at 5 or 10 meq/kg and an AV at 30 or 15, depending on the content of marine n-3s. The quality of the FO, in terms of the oxidative status, can be camouflaged by encapsulation, additives, and flavorings [10], and a variation in the oxidative status of n-3 supplements and vegetable oils has been reported [11–13].
Concerns related to a regular consumption of oxidized marine oils and negative health effects have been raised [10, 14, 15]. If lipid oxidation products from the diet are absorbed in humans, these highly reactive compounds may cause oxidative damage to macromolecules such as proteins, carbohydrate, DNA, and lipids thereby altering their function [16]. Highly reactive lipid compounds may also act as signaling molecules that alter gene functions and thereby influence health via cellular sensing mechanisms [16].

Cell studies have indicated that lipid oxidation products are involved in pathophysiological processes due to their reactivity [7, 17–19], and oxidized n-3 fatty acids have been shown to increase the antioxidant defense system and to enhance endoplasmic reticulum (ER) stress in human intestinal Caco-2/TC7 cells [20]. Some animal studies show serious biological effects from the intake of oxidized lipids [21], but there are few studies investigating the intake of oxidized lipids in concentrations more similar to daily life. However, mice fed on a high-fat diet containing weakly oxidized n-3 fatty acids for 8 weeks increased the plasma level of n-3 oxidation products and inflammatory markers [20]. The intake of oxidized vegetable oils has been shown to increase the postprandial level of plasma lipid oxidation products and markers related to coronary vascular disease in humans [22–26]. Discrepancies exist, and we have previously reported that the intake of oxidized fish oil for 7 weeks did not change the plasma levels of peroxidation products of LCPUFAs, serum level of oxidized LDL-cholesterol, or selected markers of oxidative stress and inflammation [27, 28]. However, lipid oxidation generates a variety of reactive compounds [6–8], and no single biomarker reflects the total in vivo lipid oxidation and oxidative stress status. In addition, the circulating oxidative stress markers may not be sensitive enough to reflect a local change in the cellular oxidative stress status. Other approaches including more sensitive techniques to accurately measure the influence of lipid oxidation products at a molecular level are therefore required.

Transcriptome analyses examine the mRNA transcript level in a given cell population and reflect the genes that are actively expressed at a given time. Changes in the transcriptome profile occur prior to changes in protein levels. Transcriptomics has therefore shown to be a valuable and sensitive technique measuring early changes related to a dietary challenge [29, 30]. The peripheral blood mononuclear cells (PBMCs) include monocytes and lymphocytes. In the circulation, PBMCs are exposed to environmental factors and metabolic tissues and may therefore reflect systemic health. It is well known that dietary factors modulate the gene expression in PBMCs [31–35]. In the same intervention trials as presented here, we have previously shown that the intake of high-quality FO modulated the transcriptional profile in human PBMCs and changes in the gene transcripts related to cell cycle, apoptosis, and ER stress were observed [36]. The potential of transcriptome analyses to detect early changes caused by a nutritional challenge encourages us to further investigate whether the intake of oxidized fish oil (oxFO) could alter the gene expression profile in PBMCs compared to high-quality FO in healthy subjects.

**Methods**

**Subjects**

The intervention study took place at Akershus University College, Norway, between September and December 2009. Thirty-five young healthy subjects (10 men and 25 women, aged 28.0 ± 8.1 years) with body mass index (BMI) and serum lipids within the normal range were included. Subjects enrolled in the present study are shown in Fig. 1. The detailed description of the protocol, participant recruitment and enrolment, inclusion and exclusion criteria, and compliance are published in detail elsewhere [28].

**Study design**

This study was a part of a randomized controlled double-blinded three-arm parallel group study, designed to investigate the health effects from the intake of fish oil with different oxidative quality [28]. In the present study, data from two of the intervention arms are included, as shown in Fig. 1. All subjects received 16 capsules each day, containing 8 g FO per day, of which 1.6 g was n-3 fatty acids (0.7 g/d EPA + 0.9 g/d DHA). Both FOs were originating from the same batch of cod liver oil (Gadidae sp., TINE EPA/DHA Oil 1200) provided by TINE SA (Oslo, Norway), and they were identical except for the oxidative status level. The intervention group received either oxidized oxFO (PV, 18 meq/kg; AV, 9; n, 18) or FO (PV, 4 meq/kg; AV, 3; n, 17) (Table 1). Further characterization of the encapsulated oils have previously been published [28]. The subjects were instructed to take the capsules with food (minimum two meals). Blood samples were collected at baseline and after 3 and 7 weeks of intervention. The blood samples after 7 weeks are utilized in the current study. Prior to the baseline visit, the subjects underwent a 4-week marine n-3 fatty acid washout period. During the first 3 weeks of the intervention period, the subjects conducted a fully controlled isocaloric diet. The food items given did not contain any marine n-3 fatty acids, and the food provided has previously been described in detail elsewhere [28]. The intake of dietary supplements and marine n-3 fatty acids was not allowed during the intervention period.
PBMCs and RNA isolation
After blood collection, the PBMCs were isolated by using the BD Vacutainer Cell Preparation tubes according to the manufacturer’s instructions (Becton, Dickinson and Company, NJ 07417, USA). Pellets were frozen and stored at −80 °C for further RNA isolation. Total RNA was isolated from all PBMC samples using the RNeasy Mini Kit (Qiagen) with lysis buffer-added β-mercaptoethanol according to the manufacturer’s instructions and stored at −80 °C. RNA quantity and quality measurements were performed using the ND 1000 Spectrophotometer (Saveen & Werner AB, Limhamn, Sweden) and Agilent Bioanalyser (Agilent Technologies Inc., CA 95051, USA), respectively. One sample had a RNA integrity number (RIN) score of 3.3, and all other samples were above 8 (mean = 9.6). Nanodrop analysis did not indicate any contamination in the RNA samples. The total numbers of monocytes and lymphocytes were measured in EDTA plasma at a routine laboratory (Fürst Medical Laboratory, Oslo, Norway).

Microarray hybridization
Labeled extracts were prepared using the Illumina TotalPrep RNA Amplification Kit (Illumina Inc., CA 92122, USA) according to manufacturer’s instructions. The labeled extracts were hybridized on an Illumina HumanHT-12 v4 Expression BeadChip and scanned on an Illumina HiScan microarray scanner (Illumina Inc., CA 92122, USA). Illumina GenomeStudio was used to transform bead-level data to probe-level intensity values and statistics, which were exported raw (unfiltered, non-normalized) for

### Table 1 Characterization of the encapsulated oil

|                     | oxFO   | FO    |
|---------------------|--------|-------|
| Omega-3 fatty acids |        |       |
| EPA (20: 5n-3) (g/100 g) | 9.1    | 9.0   |
| DHA (22: 6n-3) (g/100 g) | 11.2   | 11.1  |
| DPA (22 : 5n-3) (g/100 g) | 1.1    | 1.1   |
| Oxidation level     |        |       |
| PV (meq/kg)         | 18     | 4     |
| AV                  | 9      | 3     |
| TOTOX (2 × PV + AV) | 45     | 11    |
| Volatile oxidation products of omega-3 FA | | |
| Pentanal (μg/100 g) | 137.8  | 6.2   |
| 1-penten-3-ol (μg/100 g) | 132.4  | 12.8  |

oxFO oxidized fish oil, FO fish oil, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, DPA docosapentaenoic acid, PV peroxide value, AV anisidine value, TOTOX total oxidation
bioinformatic analysis. After hybridization and scanning, a manual quality control step was performed, looking at density plots and hierarchical clustering of raw probe densities. All samples, including the one with RIN < 8 were displaying good characteristics and included in further analysis.

Microarray data analyses
The Illumina intensities were quantile-normalized. To improve statistical power, probes without a detectable expression (detection \( p \) value > 0.01) in at least 10% of the samples were discarded from further analysis. From the 48,000 probes presented on the HumanHT-12 v4 microarray, 21,236 were defined as expressed in the PBMCs and included in the analyses. Changes in gene expression were obtained by calculating log2 ratios between the baseline and after 7-week intensities, and the two intervention groups were compared with regard to this ratio. Differentially expressed genes between groups were identified using the Linear Models for Microarray (Limma) data [37] package from Bioconductor (http://www.bioconductor.org) performed with the R software. For the within-group analyses, the log2 intensities at 7 weeks and baseline were compared and differentially expressed genes within each group were identified using Limma.

Genes with a nominal \( p \) value < 0.05 were defined as differentially regulated and subjected to further gene ontology, pathway, and network analyses using the Database for Annotation, Visualization and Integrated Discovery (DAVID) software tool version 6.7 (http://david.abcc.ncifcrf.gov) and MetaCore (GeneGo, division of Thomson Reuters, St. Joseph, MI, USA). For the DAVID analyses, the list of differential regulated genes was compared to a reference list of Homo sapiens and biological processes containing more than 10 genes and a false discovery rate (FDR) \( q \) value < 0.05 were considered significantly modulated. Pathways and networks identified in MetaCore with a FDR \( q \) value < 0.05 were considered significantly modulated.

Gene Set Enrichment Analyses (GSEA) (http://www.broad.mit.edu/gsea/) were applied on the genes defined as expressed in PBMCs (21,236) for comparison of the transcriptome profile between the two groups. The gene sets in the collection of C2 canonical pathways (cps) and C5 biological process (bp) from Molecular Signatures Database (MSigDB v5.0) were used separately. In addition, six gene set collections associated with oxidative stress and cardiovascular disease were created using a gene set browser (MSigDB v5.0) on the Broad Institute website (http://software.broadinstitute.org/gsea/msigdb/search.jsp) using the keywords stepwise: “oxidative AND stress,” “oxidative AND damage,” “hypoxia,” “cardiovascular,” “immune AND response,” and “inflammation.” Permutation (1000) was performed on phenotypes, and gene sets were defined as significantly changed when FDR \( q \) value < 0.25 as recommended for explorative analyses by the Broad Institute (http://www.broad.mit.edu/gsea/). The minimum information about a microarray experiment (MIAME) standards [38] were followed in the analysis and storage of data.

Results
The subjects included in the study were young and middle-aged adults (28.0 ± 8.1 years), and the characteristics of the subjects have previously been described [28]. In short, no differences in age, BMI, or serum lipids were observed between the oxFO (\( n = 18 \)) and the FO groups (\( n = 17 \)) at baseline or after 7 weeks of intervention (Table 2). Additionally, no differences in plasma fatty acids, including the level of long-chained n-3 fatty acids, were observed between the two groups after the intervention period as previously described [28]. The number of monocytes and lymphocytes were the same between the two groups at baseline and after 7 weeks of intervention (data not shown).

Gene expression profiling in PBMCs
Microarray hybridization was performed on RNA from PBMCs collected at baseline and after 7 weeks of supplementation with oxFO (\( n = 18 \)) or FO (\( n = 17 \)).

The differences in gene expression between the two groups were determined by a moderated \( t \) test (Limma), by comparing the relative change from baseline to 7 weeks of intervention among the 21,236 expressed genes. In total, 402 gene transcripts were found to be differentially expressed between the two intervention groups (\( p < 0.05 \)) (Additional file 1: Table S1). However, no gene transcripts were significantly differentially expressed (FDR \( q \) value <0.1) between the two groups when adjusting for multiple testing (Additional file 1: Table S1). To identify differences across the two intervention groups related to biological processes, pathways, and networks, we analyzed functional relationships among the 402 differentially expressed gene transcripts obtained with Limma (\( p < 0.05 \)). There was no significantly regulated biological processes, pathways, or networks between the two groups after 7 weeks using the software tools DAVID or MetaCore (FDR \( q \) value < 0.05, data not shown).

GSEA was used to test whether groups of genes involved in the same biological process or pathway were changed after intake of oxFO compared to FO among all the 21,236 defined expressed genes. We could not detect any differences between the two groups when using the C2 cp or the C5 bp gene set collection (MSigDB v5.0) (FDR \( q \) value < 0.25) (Additional files 2 and 3: Table S2 and S3). In addition, GSEA was used to test whether gene sets associated with oxidative stress, inflammation,
Table 2 Baseline characteristic and serum blood values at baseline

|          | FO (n 17) | oxFO (n 18) |
|----------|-----------|-------------|
| Male/female (n) | 5/12 | 5/13 |
| Age (year) | 25 | 23–32 |
| BMI (kg/m²) | 22.1 | 2.5 |
| Total-C (mmol/l) | 4.6 | 0.8 |
| LDL-C (mmol/l) | 2.5 | 0.8 |
| HDL-C (mmol/l) | 1.5 | 0.5 |
| TG (mmol/l) | 0.8 | 0.7–0.9 |

Data are presented as mean and standard deviation (SD) or median (25–75 percentile), and differences between the groups were calculated using independent-samples t test or Mann-Whitney U test. p values <0.05 were considered significant.

oxFO oxidized fish oil, FO fish oil, Total-C total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides

Table 3 GSEA analyses. Gene sets associated with oxidative stress and cardiovascular diseases created using a gene set browser (Molecular Signatures Database v5.0)

| GSEA gene set collection | # gene sets in collection | Regulated gene sets oxFO vs FO (FDR q value < 0.25) |
|--------------------------|---------------------------|---------------------------------------------------|
| oxidative AND stress     | 46                        | 0                                                 |
| oxidative AND damage     | 5                         | 0                                                 |
| hypoxia*                 | 65                        | 0                                                 |
| cardiovascular*           | 13                        | 0                                                 |
| immune AND response       | 147                       | 0                                                 |
| inflammation             | 29                        | 0                                                 |

# number of gene sets, FDR false discovery rate
* indicates truncated search words

Collections of gene sets were obtained using a gene set browser from the Broad Institute website http://software.broadinstitute.org/gsea/msigdb/search.jsp by the listed keywords

Table 4 Significantly changed gene transcripts identified with Limma (FDR q value < 0.1) within the oxFO or FO group after 7 weeks of intervention

| Gene         | FC within groups from baseline | FDR q value |
|--------------|-------------------------------|-------------|
| CD55         | 0.83                         | 0.00        |
| SNORD13      | 0.68                         | 0.04        |
| VNN2         | 0.90                         | 0.59        |
| SNORA12      | 0.82                         | 0.03        |
| RSNB11       | 0.92                         | 0.59        |
| VNN2         | 0.87                         | 0.62        |
| LOC80054     | 1.05                         | 0.02        |
| POLR1D       | 0.96                         | 0.66        |
| SERPINB9     | 0.98                         | 0.02        |
| RAB11FIP2    | 0.99                         | 0.02        |
| SNORD12C     | 0.91                         | 0.59        |
| BAK1         | 1.13                         | 0.04        |

oxFO oxidized fish oil, FO fish oil, FC fold change from baseline, FDR false discovery rate

Discussion

In the present study, the consumption of oxFO for 7 weeks did not alter the transcriptome profile in PBMCs in healthy subjects when compared to the intake of high-quality FO in a randomized controlled intervention study. Within-group analyses revealed a more prominent effect after intake of high-quality FO as more gene transcripts were changed from the baseline than within the oxFO group. The current study is to our knowledge the first to investigate effects at a molecular level after the intake of oxFO using high-throughput sensitive transcriptome analyses.

The intake of lipid oxidation products may disturb the normal redox state of the cell, alter normal cell function and signaling [7, 16], and ultimately lead to modulation of gene expression [39]. In a previous study with mice, the intake of moderately oxidized n-3 PUFA for 8 weeks induced oxidative stress in the intestine and enhanced significantly increased from the baseline within the oxFO group only. In addition, the gene transcripts shown in Table 2 were regulated in the same direction within the two groups after 7 weeks. To explore the biological processes modulated within each intervention group, the lists of 345 and 667 changed gene transcripts were subjected to functional analyses separately. Several biological processes were significantly modulated within each intervention group (Table 5). Modulated biological processes after 7 weeks within the oxFO group and FO group were related to translation elongation, translation, and apoptosis, whereas only cell cycle was modulated after intake of oxFO (Table 5).
plasma inflammatory markers and gene expression analyses showed an increase in the glucose-regulated protein 78 (GRP78) and glutathione peroxidase 2 (GPx2) mRNA [20]. We have previously not been able to detect changes in markers of oxidative stress such as urinary 8-iso-PGF2α, plasma α-tocopherol, plasma 4-hydroxy-2-hexenal and plasma 4-hydroxy-2-nonenal or glutathione, CAT activity, and GPx activity in erythrocytes or inflammatory markers in the same study after intake of oxFO compared to high-quality FO [27, 28]. Furthermore, the intake of oxFO, containing lipid oxidation products, did not alter biological processes or gene sets related to oxidative stress when compared to fish oil in the current study.

When the groups were analyzed separately, the mRNA level of BAK1 was significantly increased from baseline within the oxFO group. The BAK1 protein is localized to the mitochondria and functions to induce apoptosis. This protein also interacts with the tumor suppressor p53 after exposure to cellular stress [40], and the increased BAK1 mRNA level could be caused by the intake of lipid oxidation products in the oxFO group. BAK and BAX were recently shown to be involved in eicosanoid metabolism independent of apoptotic functions [41]. The increase in BAK1 mRNA may therefore be related to the eicosanoid precursor EPA and DHA, presented in equal amounts in the two fish oils. BAK1 mRNA was also increased from the baseline within the FO group, although not significantly (Table 4), and biological processes related to apoptosis were regulated within both fish oil groups.

Biological processes related to translation elongation, translation, and apoptosis were enriched within both groups, while biological processes related to cell cycle was only enriched within the oxFO group. However, we have previously shown that the intake of high-quality FO regulated gene transcripts related to apoptosis, cell cycle, and ER stress when compared to the intake of high-oleic sunflower oil [36]. Our data is in accordance with Bouwens et al.’s, who also demonstrated that the expression of genes involved in pathways related to processes such as transcription, translation, and cell cycle were regulated in PBMCs after the intake of FO (1.8 g/day EPA+DHA) for 26 weeks in elderly subjects [31]. Thus, processes related to the translation, apoptosis, and cell cycle may be modulated after the intake of fish oil independent of oxidative status. These processes and pathways are involved in normal cellular functions and may ultimately influence whole body health. We did not detect any regulated pathways or processes related to lipid metabolism, antioxidant defense, and inflammation as previously reported after n-3 supplementation [31, 42–44]. This could be explained by the inclusion of healthy subjects in the current study, and the results may be different in subjects with elevated levels of inflammation, oxidative stress, or serum lipids.

CD55 was downregulated from the baseline within both groups and independent of the oxidative status of the fish oils. CD55 is part of the complement system and has been suggested to play a role in the pathogenesis of atherosclerosis [45]. CD55 deficiency has also been shown to protect apoE−/− mice from atherosclerosis [46]. The downregulation

### Table 5 Enriched biological processes within the oxFO and FO groups after 7 weeks of intervention among the regulated genes obtained with Limma analysis (p < 0.05)

| Enriched BP oxFO                              | Fold enrichment | FDR % |
|----------------------------------------------|----------------|-------|
| GO:0006414−translational elongation          | 9.52           | 0.00  |
| GO:0007049−cell cycle                        | 2.48           | 0.02  |
| GO:0006412−translation                       | 3.49           | 0.03  |
| GO:0000280−nuclear division                  | 4.08           | 0.07  |
| GO:0007067−mitosis                           | 4.08           | 0.07  |
| GO:0000087−M phase of mitotic cell cycle      | 4.01           | 0.08  |
| GO:0048285−organellar fission                | 3.92           | 0.10  |
| GO:0000278−mitotic cell cycle                 | 3.12           | 0.11  |
| GO:0022402−cell cycle process                | 2.38           | 0.85  |
| GO:0051301−cell division                     | 3.04           | 1.19  |
| GO:0022403−cell cycle phase                  | 2.63           | 1.23  |
| GO:0042981−regulation of apoptosis            | 1.99           | 2.62  |
| GO:0043067−regulation of programmed cell death| 1.97           | 2.98  |
| GO:0010941−regulation of cell death           | 1.97           | 3.13  |
| GO:0000279−M phase                           | 2.73           | 3.15  |
| GO:0051726−regulation of cell cycle          | 2.71           | 3.34  |
| GO:0051338−regulation of transferase activity| 2.59           | 3.37  |

| Enriched BP FO                              | Fold enrichment | FDR % |
|----------------------------------------------|----------------|-------|
| GO:0006414−translational elongation          | 9.22           | 0.00  |
| GO:0006412−translation                       | 3.83           | 0.00  |
| GO:0006916−anti-apoptosis                    | 3.80           | 0.00  |
| GO:0043066−negative regulation of apoptosis  | 2.53           | 0.14  |
| GO:0043069−negative regulation of programmed cell death | 2.49 | 0.18 |
| GO:0060548−negative regulation of cell death | 2.48           | 0.18  |
| GO:0043067−regulation of programmed cell death | 1.88           | 0.23  |
| GO:0010941−regulation of cell death          | 1.87           | 0.25  |
| GO:0042981−regulation of apoptosis           | 1.85           | 0.39  |
| GO:0042254−ribosome biogenesis               | 3.36           | 2.73  |
| GO:006917−induction of apoptosis             | 2.21           | 4.20  |
| GO:0012502−induction of programmed cell death| 2.21           | 4.32  |

oxFO oxidized fish oil, FO fish oil, BP biological processes, FDR false discovery rate
of CD55 mRNA by fish oil may thus be one of the mechanisms by which fish oil can exert its beneficial effect.

The changes in the oxidative status of the oil as measured by increased PV and AV occur prior to a measurable reduction in the concentration of fatty acids. Thus, the oxidized and the non-oxidized FO contained an equal amount of fatty acids, including n-3 fatty acids (Table 1). The similar transcriptome profile may therefore be explained by the similar fatty acid profile of the FOs [28] as they originated from the same batch.

Conflicting results related to the prevention of cardiovascular diseases by marine LCPUFAs have recently been published [47]. It has been suggested that the oxidation of the marine oils may be responsible for the lack of effect [15]. A recent study investigating the effect of omega-3 supplements with different oxidation levels on circulating lipid parameters showed a reduction in plasma triglycerides independent of the oxidative status of the fish oil. However, a beneficial effect on plasma total cholesterol was only evident in the group consuming less oxidized fish oil [48]. In the current study, a more prominent effect was evident after the intake of FO as 11 gene transcripts were significantly (FDR < 0.1) changed from baseline whereas 3 within the oxFO group (Table 4). Whether this is related to the oxidative status of the fish oils is currently not known and needs further investigations.

The present study was originally designed to investigate the effect of oxFO on the circulating markers of oxidative stress, inflammation, and plasma lipids compared to high-quality FO, and the power of the study was calculated based on the relative change in plasma n-3 compared to the high-oleic sunflower oil [28]. We cannot rule out the possibility that the current study lacks the power to detect differences between the two FO groups when it comes to the transcriptome profile. However, transcriptome analyses in PBMCs represent a sensitive high-throughput method to detect changes caused by diet [30]. To increase the power in the current study, we included analyses where genes were grouped based on involvement in the same biological process, pathway, or network.

The strengths of the present study are that the study design was performed as a blinded randomized controlled trial with high compliance, as described in more detail elsewhere [28]. The transcriptome analyses have been performed with an exploratory approach where the identification of regulated gene transcripts, biological processes, and networks was done with several data analysis strategies. The major limitation is the relatively low daily dose of oxidized lipids (PV/AV) administered and the relatively short intervention period. The study group included healthy subjects, and we cannot rule out that by using another study group more susceptible to the intake of oxFO, this would have led to different results. There is also a chance that other cellular compartments or tissues such as the intestine may have been affected by the intake of oxFO in the present study.

Conclusion
By using a transcriptome approach, we aimed to investigate the effects at the molecular level prior to changes in circulating markers. The results demonstrate that the short-term consumption of oxidized fish oil in healthy subjects did not alter the transcriptome profile in PBMCs compared to the intake of high-quality FO. Whether these results are applicable for other oxidized marine oils, longer interventions, or valid in subjects with elevated levels of inflammation and oxidative stress needs to be addressed.

Additional files

Additional file 1: Table S1. Significantly changed gene transcripts (p < 0.05) between the oxFO and FO groups determined by a moderated t test (Limma), by comparing the relative change from the baseline to 7 weeks of intervention. oxFO oxidized fish oil, FO fish oil, FC fold change from baseline, FDR false discovery rate. (XLSX 34 kb)

Additional file 2: Table S2. GSEA analyses applied on the genes defined as expressed in PBMCs (21,236) for comparison of the transcriptome profile between the two groups oxFO vs FO. Gene sets in the C2 cp collection were used. ES enrichment score, NES normalized enrichment score. (XLSX 33 kb)

Additional file 3: Table S3. GSEA analyses applied on the genes defined as expressed in PBMCs (21,236) for comparison of the transcriptome profile between the two groups oxFO vs FO. Gene sets in the C5 bp collection were used. ES enrichment score, NES normalized enrichment score. (XLSX 25 kb)

Abbreviations
AV: anisidine value; CHD: coronary heart disease; FC: fold change; FDR: false discovery rate; FO: fish oil; LCPUFAs: long-chain polyunsaturated fatty acids; meq/kg: milliequivalents per kilogram; oxFO: oxidized fish oil; PBMCs: peripheral blood mononuclear cells; PV: peroxide value.

Acknowledgements
The microarray analyses were performed by the Genomics Core Facility, Norwegian University of Science and Technology, and NMC—a national technology platform supported by the Functional Genomics (FUGE) program of the Research Council of Norway.

Funding
This study was supported by the Research Council of Norway (project no. 184813/110), Oslo, the Akershus University College of Applied Sciences, Norway; the University of Oslo, Norway; and the Throne Holst Foundation for Nutrition Research.

Authors’ contributions
MCWM designed research and developed the research plan, carried out the microarray and statistical analyses, interpretation of data and drafted the manuscript. IO designed research and developed the research plan, performed statistical analyses and drafted the manuscript. C-CG carried out microarray analyses. ER carried out microarray analyses. AN designed research and developed research plan. KWB designed research and developed research plan. AK carried out statistical analyses and interpretation of data. GIAB designed research and developed the research plan, interpretation of data. KBH designed research and developed the research plan, interpretation of data and drafted the manuscript. All authors read and approved the final manuscript.
Competing interests
Kirsti W. Brønner is a clinical nutritionist/project manager at the TINE SA R&D Center, Norway, with no financial interest. Kirsten B. Holven and Stine M. Ulven have received research funding from TINE SA but declare no conflict of interest. Mari C. W. Myhrstad, Inger Ottestad, Clara-Cecille Günsther, Einar Ryeng, Marit Holden, Astrid Nilsson, Achim Kohler, and Grethe I. A. Borge declare no conflict of interest.

Ethics approval and consent to participate
Written informed consent for participation and study approval from the Norwegian Regional Committee of Medical and Health Research Ethics (REC) south east (approval no. 6.2008:2215), the Norwegian Social Science Data Services (approval no. 21924), and the University College of Applied Sciences were obtained. The study was conducted in accordance with the guidelines in the Declaration of Helsinki. The study was registered at www.clinicaltrial.gov (no. NCT01034423).

Author details
1Department of Health, Nutrition and Management, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences, P.O. Box 452, Olavii pl. 0130 Oslo, Norway. 2Department of Nutrition, Institute for Basic Medical Sciences, University of Oslo, P.O. Box 1046Blindern, 0317 Oslo, Norway. 3Norwegian Computing Center, 0314 Oslo, Norway. 4Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, 7489 Trondheim, Norway. 5Nofima AS, Norwegian Institute of Food, Fisheries and Aquaculture Research, PB 210, Aas N-1431, Norway. 6TINE SA, Centre for Research and Development, P.O. Box 2/Albakken, 0515 Oslo, Norway. 7Department of Mathematical Sciences and Technology (IMT), Norwegian University of Life Sciences, 1432 Ås, Norway. 8Norwegian National Advisory Unit on Familial hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital Rikshospitalet, P.O Box 4950Nydalen, Oslo, Norway.

Received: 21 August 2015 Accepted: 6 April 2016
Published online: 31 May 2016

References
1. Dietary supplementation with n-3 polysaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. 1999 Lancet 354:447-55.
2. Yokoyama M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1009–8. doi:10.1016/S0140-6736(07)60257-3.
3. Gebeau SK, Prota TL, Harris WS, Kris-Etherton PM. n-3 fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am J Clin Nutr. 2006;83:312S–35.
4. Lichtenstein AH et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol. 2006;26:2186–201.
5. Mozaffarian D. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Clin Nutr. 2008;87:1991S–5. doi:10.3945/ajcn.2007.27389.
6. Catula A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem Phys Lipids. 2009;157:1–11. doi:10.1016/j.chemphys.2008.09.004.
7. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:181–128.
8. Siddiqui RA, Harvey K, Stillwell W. Anticancer properties of products of docosahexaenoic acid. Chem Phys Lipids. 2008;153:47–56. doi:10.1016/j.chemphys.2008.02.009.
9. (GOED) GOEraDo-s (2006) Global Organization for EPA and DHA omega-3s (GOED)
10. Myhrstad et al. (2012) Description of the processes in the value chain and risk assessment of decomposition substances and oxidation products in fish oils (08-504-4-final). vol 08-504-4-final.
11. Albert BB et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928. doi:10.1038/srep07928.
12. Halvorsen BL, Blomhoff R. Determination of lipid oxidation products in vegetable oils and marine omega-3 supplements. Food Nutr Res. 2011;55 doi:10.3402/fnr.v55i0.5792.
13. Kolanowski W. Omega-3 LC PUFA contents and oxidative stability of encapsulated fish oil dietary supplements. Int J Food Prop. 2010;13:498–511. doi:10.1016/j.ijfoodprop.2010.02.025/222.
14. (BIOHAZ) EPOBH. Scientific opinion on fish oil for human consumption. Food hygiene, including rancidity. EFSA J. 2010;8:1874.
15. Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of marine omega-3 supplements and human health. Biomed Res Int. 2013;2013:2013.
16. Halliwell B, Chetico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993;57:715S–24. discussion 7245-7255.
17. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med. 2004;37:469–84. doi:10.1016/j.freeradbiomed.2004.05.032.
18. Riahi Y, Cohen G, Shammi O, Sasson S. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am J Physiol Endocrinol Metab. 2010;299:E879–86. doi:10.1152/ajpendo.00580.2010.
19. Sayre LM, Lin D, Yuan Q, Zhu X, Tang X. Protein adducts generated from products of lipid oxidation: focus on HNE and one. Drug Metab Rev. 2006;38:651–75. doi:10.1080/03602530600955908.
20. Awada M et al. Dietary oxidized n-3 PUFA induce oxidative stress and inflammation: role of intestinal absorption of 4-HHE and reactivity in intestinal cells. J Lipid Res. 2012;53:6069–80. doi:10.1194/jlr.M026719.
21. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr. 1993;57:7795–85. discussion 7855-7865.
22. Staprans I, Hardman DA, Pan XM, Feingold KR. Effect of oxidized lipids in the diet on oxidized lipid levels in postprandial serum chylomicrons of diabetic patients. Diabetes Care. 1999;22:300–6.
23. Staprans I, Rapp JH, Pan XM, Kim KY, Feingold KR. Oxidized lipids in the diet are a source of oxidized lipid in chylomicrons of human serum. Arterioscler Thromb. 1994;14:1900–5.
24. Sutherland WH, de Jong SA, Hessian PA, Williams MJ. Ingestion of native and thermally oxidized polysaturated fats acutely increases circulating numbers of endothelial microparticles. Metabolism. 2010;59:446–53. doi:10.1016/j.metabol.2009.07.033.
25. Sutherland WH, de Jong SA, Walker RJ, Williams MJ, Murray Skeaff C, Duncan A, Harper M. Effect of meals rich in heated olive and safflower oils on oxidation of postprandial serum in healthy men. Atherosclerosis. 2002;160:195–203.
26. Wallace AJ, Sutherland WH, Mann JJ, Williams SM. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur J Clin Nutr. 2001;55:951–8. doi:10.1038/sj.ejcn.1601250.
27. Ottestad I et al. Intake of oxidised fish oil does not affect circulating levels of oxidised LDL or inflammatory markers in healthy subjects. Nutr Metab Cardiovasc Dis. 2013;23:e3. doi:10.1016/j.numecd.2012.08.002.
28. Ottestad I et al. Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial. Eur J Nutr. 2011;50:12. doi:10.1007/s00394-010-05958.
29. Afman L, Milenkovic D, Roche HM. Nutritional aspects of metabolic inflammation in relation to health-insights from transcriptomic biomarkers in PBMC of fatty acids and polyphenols. Mol Nutr Food Res. 2014. doi:10.1002/mnr.20055.
30. de Mello VD et al. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr. 2009;89:415–24. doi:10.3945/ajcn.2009.27680.
31. de Mello VD et al. The effect of fatty or lean fish intake on inflammatory gene expression in peripheral blood mononuclear cells of patients with coronary heart disease. Eur J Nutr. 2009;48:447–55. doi:10.1007/s00394-009-0033-y.
32. Kolehmainen M et al. Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome. Mol Nutr Food Res. 2012;56:1501–10. doi:10.1002/mnfr.201200195.
33. Radler U et al. A combination of (omega-3) polysaturated fatty acids, polyphenols and L-carnitine reduces the plasma lipid levels and increases the expression of genes involved in fatty acid oxidation in human
35. van Dijk SJ, Feskens EJ, Bos MB, de Groot LC, de Vries JH, Muller M, Afman LA. Consumption of a high monounsaturated fat diet reduces oxidative phosphorylation gene expression in peripheral blood mononuclear cells of abdominally overweight men and women. J Nutr. 2012;142:1219–25. doi:10.3945/jn.111.155283.

36. Myhrstad MC et al. Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach. J Intern Med. 2014;276:498–511. doi:10.1111/joim.12217.

37. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3. doi:10.2202/1544-6115.1027.

38. Brama A et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29:365–71. doi:10.1038/ng1001-365.

39. Allen RG, Tresini M. Oxidative stress and gene regulation. Free Radic Biol Med. 2000;28:463–99.

40. Mathai JP, Germain M, Shore GC. BH3-only BIK regulates BAX, BAK-dependent release of Ca2+ from endoplasmic reticulum stores and mitochondrial apoptosis during stress-induced cell death. J Biol Chem. 2005;280:23829–36. doi:10.1074/jbc.M500800200.

41. Zhang T, Walensky LD, Saghatelian A. A nonapoptotic role for BAX and BAK in eicosanoid metabolism. ACS Chem Biol. 2015;10:1398–403. doi:10.1021/acschembio.5b00168.

42. Schmidt S, Stahl F, Mutz KO, Scheper T, Hahn A, Schuchardt JP. Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial. Lipids Health Dis. 2012a 11:105 doi:10.1186/1476-511X-11-105

43. Schmidt S, Stahl F, Mutz KO, Scheper T, Hahn A, Schuchardt JP. Transcriptome-based identification of antioxidative gene expression after fish oil supplementation in normo- and dyslipidemic men. Nutr Metab 2012b 9:45 doi:10.1186/1743-7075-9-45

44. Vedin I et al. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One. 2012;7:e35425. doi:10.1371/journal.pone.0035425.

45. Kostner KM. Activation of the complement system: a crucial link between inflammation and atherosclerosis? Eur J Clin Invest. 2004;34:800–2. doi:10.1111/j.1365-2636.2004.01431.x.

46. Lewis RD, Perry MJ, Guschina IA, Jackson CL, Morgan BP, Hughes TR. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. Am J Pathol. 2011;179:1601–7. doi:10.1016/j.ajpath.2011.06.015.

47. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–33. doi:10.1001/jama.2012.11374.

48. Garcia-Hernandez VM, Gallar M, Sanchez-Soriano J, Micoc V, Roche E, Garcia-Garcia E. Effect of omega-3 dietary supplements with different oxidation levels in the lipidic profile of women: a randomized controlled trial. Int J Food Sci Nutr. 2013;64:993–1000. doi:10.3109/09637486.2013.812619.